This study provides evidence that melanoma patients receiving PD-1 inhibitor therapy in combination with CTLA-4 inhibitor therapy are at greater risk of experiencing immune-related neurologic adverse events than patients on anti-PD-1 monotherapy treatment regimens. Here, CTLA4 is linked to melanoma.